Randomized transcoronary delivery of CD34+ cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of 99mTc-labeled cells activity by Musialek, Piotr et al.
ORIGINAL ARTICLE
Randomized transcoronary delivery of CD34
+
cells with perfusion versus stop-ﬂow method in
patients with recent myocardial infarction: Early
cardiac retention of
99mTc-labeled cells activity
Piotr Musialek, MD, DPhil,
a,d Lukasz Tekieli, MD,
a,d
Magdalena Kostkiewicz, MD, PhD,
a,d Marcin Majka, PhD,
b
Wojciech Szot, MD, PhD,
d Zbigniew Walter, MD,
c Anna Zebzda, PhD,
b
Piotr Pieniazek, MD, PhD,
a,d Andrzej Kadzielski, RN, MSc,
d
R. Pawel Banys, MSc,
d Maria Olszowska, MD, PhD,
a,d
Mieczyslaw Pasowicz, MD, PhD,
d Krzysztof Zmudka, MD, PhD,
a,d
and Wieslawa Tracz, MD, PhD
a,d
Background. For transcoronary progenitor cells’ administration, injections under ﬂow
arrest (over-the-wire balloon technique, OTW) are used universally despite lack of evidence for
being required for cell delivery or being effective in stimulating myocardial engraftment. Flow-
mediated endothelial rolling is mandatory for subsequent cell adhesion and extravasation.
Methods. To optimize cell directing toward the coronary endothelium under maintained
ﬂow, the authors developed a cell-delivery side-holed perfusion catheter (PC). Thirty-four
patients (36-69 years, 30 men) with primary stent-assisted angioplasty-treated anterior MI
(peak TnI 151 [53-356]ng/dL, mean[range]) were randomly assigned to OTW or PC autologous
99Tc-extametazime-labeled bone marrow CD34
1 cells (4.34 [0.92-7.54] 3 10
6) administration at
6-14 days after pPCI (LVEF 37.1 [24-44]%). Myocardial perfusion (
99mTc-MIBI) and labeled
cells’ activity were evaluated (SPECT) at, respectively, 36-48 h prior to and 60 min after
delivery.
Results. In contrast to OTW coronary occlusions, no intolerance or ventricular arrhythmia
occurred with PC cells’ administration (P < .001). One hour after delivery, 4.86 [1.7-7.6]% and
5.05 [2.2-9.9]% activity was detected in the myocardium (OTW and PC, respectively, P 5 .84).
Labeled cell activity was clearly limited to the (viable) peri-infarct zone in 88% patients,
indicating that the infarct core zone may be largely inaccessible to transcoronary-administered
cells.
Conclusions. Irrespective of the transcoronary delivery method, only &5% of native (i.e.,
non-engineered) CD34
1 cells spontaneously home to the injured myocardium, and cell reten-
tion occurs preferentially in the viable peri-infarct zone. Although the efﬁcacy of cell delivery is
not increased with the perfusion method, by avoiding provoking ischemic episodes PC offers a
rational alternative to the OTW delivery. (J Nucl Cardiol 2011;18:104–16.)
Key Words: CD 34
1 cells Æ myocardial infarction Æ cellular therapy Æ cell delivery techniques
From the Department of Cardiac and Vascular Diseases, John Paul II
Hospital, Institute of Cardiology,
a Jagiellonian University, Krakow,
Poland; Department of Transplantation,
b Jagiellonian University,
Krakow, Poland; Department of Hematology,
c Jagiellonian Univer-
sity, Krakow, Poland; and John Paul II Hospital,
d Krakow, Poland.
Parts of this work have been presented to the Transcatheter Cardio-
vascular Therapeutics (Novel Concepts and Innovative Devices—
Invited Faculty Session) and to the European Society of Cardiology
(Young Investigator Awards).
Supported by Ministry of Science and Higher Education (Poland)
(project PBZ-KBN-099/P05/2003) and ‘For the Heart Foundation’
in Krako ´w, Poland. AZ was a recipient of the City of Krakow
Research Scholarship.
Received for publication Mar 25, 2010; ﬁnal revision accepted Sep 20,
2010.
Reprint requests: Piotr Musialek, MD, DPhil or Magdalena
Kostkiewicz, MD, PhD, Department of Cardiac and Vascular Dis-
eases, John Paul II Hospital, Institute of Cardiology, Jagiellonian
University, ul. Pradnicka 80, 31-202 Krakow, Poland; pmusi-
alek@szpitaljp2.krakow.pl or mkostkiewicz@szpitaljp2.krakow.pl.
1071-3581/$34.00
Copyright  2010 The Author(s). This article is published with open
access at Springerlink.com
doi:10.1007/s12350-010-9326-z
104INTRODUCTION
Progenitor cell transplantation is anticipated to
complement current revascularization strategies in acute
myocardial infarction (MI) by stimulating endogenous
repair and, potentially, by replacing part of the damaged
microvascular and myocardial tissue. Initial reports of
successful small-animal experiments led to direct, rapid
attempts of their translation in the clinical setting.
Today, transcoronary transfer of autologous bone mar-
row cells has been performed in more than 1,500
patients with a recent MI who were included in over 20
clinical studies.
1-3 Meta-analyses of those studies indi-
cate, disappointingly, that the long-term beneﬁt is
clinically minimal or absent.
1,2
Efﬁcient delivery of progenitor cells to the recent
infarct injury zone is a pre-requisite for any effect of cell
therapy.
4,5 For transcoronary cell administration, past
and current clinical studies have universally
1-3 adopted a
‘‘stop-ﬂow’’ technique, using the central lumen of an
inﬂated over-the-wire balloon catheter positioned in the
stent in infarct-related artery (IRA).
6,7 Injecting the cells
under ﬂow arrest has been assumed to ‘‘allow for
adhesion and potential transmigration of the infused
cells through the endothelium’’
7-9 or ‘‘prolong contact
time for cellular migration to the damaged tissue’’.
10
Interestingly, the stop-ﬂow method was never shown to
be required for progenitor cell delivery or to be effective
in enhancing myocardial retention of the cells.
6,11
Evaluation of different transcoronary cell adminis-
tration techniques in man has been considered essential
for further development of cellular therapies.
6,11-13
Evidence indicates that, similar to leukocytes, ﬂow-
mediated undisturbed ‘‘physiological’’ rolling in contact
with endothelium is a primary, mandatory step in pro-
genitor cells trafﬁcking.
5 Progenitor cells endothelial
rolling (mediated largely by selectins) is a ‘‘primer’’ for
integrin-mediated downstream adhesion to the activated
endothelium, and chemokine-mediated transendothelial
diapedesis (extravasation) and migration to the injured
tissue.
4,5 In addition, blood ﬂow-related hydrodynamic
forces are known to play an important role in the cell
rolling and adhesion process by interacting, for instance,
with the selecin bonds.
14 This suggested that cell
administration under maintained coronary ﬂow might be
more effective than the coronary-occlusive delivery.
The perfusion technique, including the employment
of side-holed catheters, has been in clinical use since
1990s for transcoronary drug administration under
maintained coronary ﬂow.
15,16 More recently, the per-
fusion technique was found effective in transcoronary
gene delivery in the pig heart in situ.
17 Initially, in a
pilot study the authors tested the feasibility of autolo-
gous bone marrow cell delivery through a perfusion
catheter intended for intracoronary drug administration.
4
Currently, the authors have developed a side-holed
perfusion catheter (PC) dedicated to cell delivery under
maintained coronary ﬂow and, in a randomized study in
man, the authors have quantiﬁed early myocardial
uptake of autologous CD34
? cells administered with the
stop-ﬂow versus perfusion technique.
METHODS
Cell-Delivery Perfusion Catheter
The side-hole design of the perfusion catheter was chosen
because this design was previously shown to be optimal for
towards-the-wall delivery.
15,16 For bench testing, the authors
designed PCs with the following parameters: (1) lumen size of
0.9 or 1.2 mm; (2) side-hole number of 8, 10, 12, 15, or 20;
and (3) side-hole diameter of 0.10, 0.15, or 0.20 mm. All PCs
were designed in rapid exchange (RX) system, with two
independent lumens (one, RX, for a 0.014 inch guide-wire, and
the other for cell-suspension injection). For each catheter, in a
system mimicking a coronary artery, the authors evaluated the
delivery pressure required to achieve optimal out-ﬂow from a
maximal number of side-holes (cell-suspension solution).
Catheters with lumen size of 0.9 mm yielded no outﬂow of the
cell-suspension solution for the hole size of 0.10 mm and, for
hole sizes of 0.15 or 0.20 mm, only poor outﬂow which,
however, required delivery pressures of at least 10-15 barr
(N.B. manual inﬂation pressure is 3-4 barr). Catheters with
side-hole numbers of 10, 12, 15, or 20 and/or side-hole sizes
of 0.20 or 0.25 mm required very high inﬂation pressures
(10-20 barr) to overcome drop-like outﬂow of the cell-sus-
pension solution and thus they were rejected to avoid baro-
trauma to the cells. The PC with lumen size of 1.2 mm and 8
side holes of 0.15 mm each yielded optimal out-ﬂow from all
side holes at 3 barr; thus, this design was selected for our
clinical study. An order was placed, according to our speciﬁ-
cations, with a producer of catheterization equipment (Balton
Ltd, Poland). In contrast to the over-the-wire (OTW) balloon
catheter, the PC did not require guidewire pull-back for cell
delivery; thus it could offer guidewire security of the artery
during administration of progenitor cells.
Clinical Study Outline
Ourworkinghypothesiswasthat‘‘physiological’’delivery
of autologous CD34
? cells through the perfusion technique
(PC) might be associated with a greater early myocardial
retention than the conventional OTW (under ﬂow arrest) cells
administration. The study was carried out in humans because
the perfusion technique is not new to clinical use,
15,16 and
animal studies are unlikely to precisely determine the effec-
tiveness of cell delivery in patients.
18 Nuclear-tracer cell
labeling was employed as the current method of choice for
high-sensitivity in vivo imaging of the transplanted cells in
man.
19-21 Radionuclide labeling (the nuclear tracer and/or its
carrier), however, can be harmful to the therapeutic cells
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potential therapeutic) capacity.
19,20 Also, administration of
nuclear-tracer labeled cells is associated with an additional
radiation burden to the patient.
19,20 For these reasons, and
consistent with the size of published hypothesis-testing ran-
domized stem-cell studies in man,
22 the Institutional Review
Board approved a study in a maximum of 36 patients (2:1
randomization, see below) and required mandatory data
analysis prior to any potential submission for study extension.
The study conformed with the Declaration of Helsinki. It
included unselected, consented (informed written consent)
patients with primary angioplasty (pPCI)-treated ﬁrst myo-
cardial infarction (anterior location; infarct related artery
(IRA) = left anterior descending coronary artery) and a deﬁ-
nite infarct-related myocardial injury manifest as peak
troponin I[50 ng/mL and left ventricular ejection fraction
(LVEF) \45% when screened by echocardiography at
4-8 days after pPCI.
Myocardial Imaging
Myocardial perfusion was evaluated at 36-48 hours prior
to cell transfer by single-photon emission computed tomog-
raphy (SPECT,
99mTc-MIBI, nitroglycerin enhancement
23).
LVEF was also determined by gated-SPECT.
23
Cell Harvesting, Isolation, and Labeling
On the morning of the day of cell transfer (6-14 days after
pPCI), bone marrow (80-120 mL) was harvested from the iliac
crest.
3,7 Mononuclear cells were separated with Ficoll
TM,
3,7
and CD34
? cells were immunomagnetically selected with
mononuclear antibodies coupled to magnetic beds (Midi-
MACS System, Miltenyi Biotec GmbH).
3 The average number
of mononuclear cells was 3.46 9 10
8 (range 0.91 9 10
8-
5.48 9 10
8), and CD34
? cell yield was 4.34 9 10
6 (range
0.92 9 10
6-7.54 9 10
6).
After transfer to a nuclear medicine lab, the cells were
labeled with
99mTc-extametazime (Ceretec, Amersham)
according to a previous protocol.
24 In brief, for each subject all
the harvested cells were incubated for 30 min (37C) with
99mTc-extametazime (110 MBq);
24 a lipophilic compound that
turns hydrophilic after crossing the cell membrane and remains
intracellular during cell tracking.
20 Then the cells were washed
thrice and re-suspended in 10 mL heparinized (10 IU/mL)
saline.
24 For cell labeling, the authors used 99mTc-extameta-
zime and not
111In-oxine because the latter was shown to have
a substantial detrimental effect on the integrity, viability,
migration and proliferation of hematopoetic progenitor
cells,
25,26 while
99mTc-extametazime is considered signiﬁ-
cantly less toxic.
27,28 Radioactivity of the labeled cells was
determined with a rate meter (PTW-Curiementor 2). Cell
viability was assessed with trypan blue dye exclusion assay
4,29
prior to and after labeling. The number of dead cells (not
excluding the dye—thus stained blue) was examined under
microscope per 500 cells and expressed as percentage.
Patient Randomization and Cell Transfer
The study was designed with 2:1 randomization (PC :
OTW) because unequal randomization can be used to enhance
the likelihood of detecting a difference between a ‘‘new’’
versus the more established method, particularly if some data
concerning the latter are already available in the public
domain.
30,31 For the purpose of randomization of a maximum
of 36 patients, 39 closed envelopes were prepared and inside
each there was a card indicating ‘‘PC’’ or ‘‘OTW’’
(26‘‘PC’’:13‘‘OTW’’). Each time, while the patient was
installed on the catheterization table for cell delivery, one of
these envelopes was randomly selected by the study nurse.
OTW delivery was performed according to the typical protocol
used by other investigators (3 injections of 3.3 mL, each bal-
loon inﬂation for up to 3 min)
3,7,9,10 whereas for PC-delivery,
the cell suspension volume was expanded to 30 mL, and 3
rapid injections (each of 10 mL) were performed. For both the
modes of cell transfer, the delivery catheter was placed in the
stent implanted during the pPCI 6-14 days earlier, and there
were 3 min breaks between each injection.
3,7,9
Quantiﬁcation of the Magnitude of Cells’
Myocardial Uptake
A whole-body planar (static) scan and cardiac tomo-
graphic (SPECT) images were acquired 60 min after
transcoronary cell transfer. For (off-line) quantiﬁcation of
early myocardial uptake of the labeled CD34
? cells, the left
ventricle (LV) was delineated on a whole-body planar scan
image,
28 and the number of LV counts was expressed as %
total counts.
28,32 In a similar fashion, percent activity was
determined for other organs,
28,33 and percent activity was
taken as an index of % early cells’ retention.
28,32,33
Determination of the Cells’ Myocardial
Uptake Zone
To determine the zone(s) of myocardial uptake of CD34
?
cells, SPECT images of
99mTc-labeled cells’ activity were
integrated with the corresponding SPECT images of myocar-
dial perfusion (3D-CardioFusion algorithm, CardioFusion
application on Leonardo workstation VE30A/VE30B, SYNGO
MMWP, Siemens; regions of interest deﬁned by common
reference points according to software manual).
Statistical Analysis
Variables are presented as mean ± SEM (range). For
between-group comparisons Mann-Whitney test for indepen-
dent samples was used. Correlations were evaluated with
Spearman’s coefﬁcient. For within-group comparisons
ANOVA was used. Statistical signiﬁcance was at P\.05.
106 Musialek et al Journal of Nuclear Cardiology
Transcoronary delivery of cellular therapies January/February 2011RESULTS
Thirty-four patients (30 men) aged 36-69 years
were recruited. The OTW- and PC-group were similar
with respect to demographic, clinical, and laboratory
characteristics (Table 1). The CD34
? cell number, and
the labeled cells’ viability and activity were also similar
(Table 2). Labeling efﬁciency, deﬁned as the fraction of
label retained by the cells, was 65.4 ± 2.1% (43.7-
77.8%) and was not different between the study groups
(64.6 ± 3.2% vs 66.1 ± 2.6%). The number of CD34
?
cells correlated with their activity (r = 0.74, P\.05,
not shown) and the labeling procedure had a small but
signiﬁcant effect on the cell viability (Table 2). Fol-
lowing labeling, the
99mTc radiation burden per cell
(cells total activity/cell number) was 23 ± 3 Bq.
In the majority of OTW patients (n = 10/13; 77%)
the cell infusion time (i.e., the duration of in-stent
occlusions of the LAD) was limited by occlusion
intolerance manifesting as increasing chest pain and/or
progressive ST-segment displacement. In addition, there
was one event of the IRA occlusion-triggered ventricular
tachycardia (this occurred in our third OTW patient, at
47th second of the second balloon inﬂation to inject the
cells and was preceded by increasing ST elevation,
Figure 1). Since others
34 have reported a similar
observation (malignant arrhythmias provocation by the
IRA OTW-balloon occlusions to deliver the progenitor
cells), the authors have not extended the balloon inﬂa-
tion time over the point of increasing intolerance
(average occlusion time was 69 s, 82 s, and 89 s for the
1st, 2nd, and 3rd occlusion, respectively).
In contrast to the OTW group, in the 21 PC-patients
there were no signs of symptoms of cell-delivery intol-
erance (10/13 vs. 0/21, P\.001).
One hour after transcoronary cell delivery, the
percent myocardial activity (an index of early myocar-
dial retention of cells)
14,17,18 was 4.86 ± 0.49 (mean ±
SEM, 95% CI 3.32-6.58, range 1.7-7.6) in the OTW
group and 5.05 ± 0.48 (95% CI 3.58-6.27, range 2.2-
9.9) in the PC group (P = .84). This indicated that the
coronary non-occlusive cell delivery did not lead to a
higher early myocardial retention of autologous CD34
?
cells (Figures 2, 3). Tracer uptake in the liver, lungs,
spleen, bowel, and urinary bladder was also similar and
not statistically different in the OTW- versus PC-group
(Table 2).
Qualitative evaluation of the cells’ myocardial
uptake zone (by integrating SPECT images of myocar-
dial perfusion and SPECT images of the cells’ uptake)
revealed two distinct patterns that were independent of
the method of cell delivery (Figure 4I, II). In 88%
patients (n = 30/34) the early engraftment was clearly
limited to the peri-infarct zone, with no detectable
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no-perfusion (central infarct) zone. A small proportion
of patients (12%, n = 4/34) displayed a diffuse infarct
injuryzoneradioactivityuptake(examplesinFigure 2II);
this occurred only if myocardial perfusion was present
throughout the infarct injury zone (Figure 4II, A1-A3).
The diffuse pattern of engraftment occurred in subjects
with the smallest MIs (peak troponin, and CK-MB in the
1st quartile; LVEF in the 4th quartile; the values of
55.7 ng/mL, 376 U/L, and 42.6% in contrast to those in
patients with the peri-infarct engraftment pattern where
the respective mean values were 163.7 ng/mL, 620 U/L
and 32.1%, P\.05 for all).
DISCUSSION
This study is the ﬁrst human study on visualization
and quantiﬁcation of early retention of CD34
? cells
delivered transcoronary with a non-occlusive technique.
Our principle ﬁndings are as follows. First, in contrast to
OTW coronary-occluding technique, no intolerance or
ventricular arrhythmia occur in patients with a recent MI
with cell administration through side-holed perfusion
catheter dedicated to cell delivery. Secondly, irrespec-
tive of the transcoronary delivery method, early
myocardial uptake of
99mTc activity is in the order of
&5% (range from &2% to &10%), consistent with the
idea that only a small fraction of native (non-engi-
neered) CD34
? cells spontaneously homes to the injured
myocardium. Moreover, in the vast majority of patients
early myocardial retention of radioactivity is limited to
the (viable) peri-infarct zone, indicating that the infarct
core zone is not directly accessible to the transcoronary-
administered cells.
Coronary Occlusive Versus Non-Occlusive
Cell-Delivery: The Rationale
For transcoronary cell delivery, clinical studies have
universally
1-3,7,8 adopted the stop-ﬂow technique that is
based on the use of the central lumen of a coronary-
occluding OTW balloon catheter positioned in the stent.
To deliver the cells, the OTW balloon is inﬂated leading
to a ﬂow arrest in the epicardial artery, the guidewire is
then removed and the cell suspension is injected.
7 An
effective ﬂow arrest on balloon inﬂation
35 precludes
physiological ﬂow-mediated endothelial rolling of the
cells in the epicardial artery during cells injection. Then,
on balloon deﬂation there is an instantaneous reactive
increase in the epicardial and capillary ﬂow velocity
(with normal values exceeded by C2-fold
35). Flow-
related hydrodynamic forces affect selecin bonds that
physiologically form between the administered cells and
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11 Moreover, the ‘‘waterfall’’ effect
35
of reactive hyperemia can contribute to a rapid, unde-
sired cell wash-out, thereby limiting the proportion of
cells that can effectively interact with the activated
endothelium situated downstream (i.e., in the injury
zone) and trans-migrate into the injury zone. In the pig
model of myocardial infarction, dynamic scintigraphy of
[
18F]-ﬂuorodezoxyglucose (FDG)-labeled progenitor
cells recently conﬁrmed a rapid loss of ca. 80% cells on
OTW balloon deﬂation,
21 whereas in humans repeated
balloon occlusions of the infarct artery for cell delivery
were reported to stimulate adverse regional no-ﬂow in
the infracted myocardial tissue.
36 In addition, OTW-cell
delivery can be associated with the triggering of
malignant ventricular arrhythmias
4,34 (Figure 1). This
effect is not unexpected, since the forming myocardial
scar is an arrhythmic substrate and ischemia is a well-
known arrhythmic trigger. Since prior study protocols
included the OTW-balloon IRA occlusions for periods
ranging from 3 min
1-3,7 to 9 ± 6 min,
8 the pro-arrhyth-
mic effect of IRA occlusions for cell delivery is likely to
have been under-reported.
We hypothesized that a non-occlusive, endothe-
lium-targeting cells’ delivery through a side-holed PC
might enhance physiological homing (1) by enabling
undisturbed physiological rolling in contact with the
endothelium of a greater proportion of infused CD34
?
cells (increase in an effective contact probability), and
(2) by avoiding the accelerated cell wash-out on balloon
deﬂation.
The Magnitude of Early Myocardial
Radioactivity Uptake (
99mTc-Labeled Cells)
Early myocardial uptake of CD34
? cells radioac-
tivity was not different in PC- and OTW-delivery
(&5%; Table 2, Figure 3). A similar uptake (5.5%) was
determined by PET for
18F-FDG-labeled peripheral
CD34
? cells 1 hour after conventional OTW-delivery.
37
These results do not conﬁrm earlier pilot ﬁndings that
suggested a higher myocardial uptake of selected
CD34
? cells than the uptake of unselected mononuclear
bone marrow cells (14%-39% vs. 1.3%-2.6%, for each
group n = 3, PET imaging of
18F-FDG labeled cells).
29
Indeed, the ineffectiveness of ex vivo selection of
CD34
? from the pool of mononuclear cells on the pro-
portion of myocardial engraftment might underlie the
lack of outcome difference for the use of selected
CD34
? versus unselected mononuclear cells in a recent
large randomized study.
3
Why would a ‘‘physiological’’ delivery not trans-
late into an increased early engraftment of CD34
? cells?
First, the side-holed PC may have failed in the intended
delivery of a signiﬁcant proportion of the cells to the
Figure 1. Ventricular tachycardia (VT) associated with infarct-related artery (LAD)—occlusive
cell delivery (2nd OTW-balloon inﬂation, man 53 years, day 7 after pPCI, LVEF 37%, ECG
recording at 25 mm/s coupled to the angiocardiograph, Siemens Axiom Artis). Immediately prior to
VT the patient reported increasing chest pain (note ST-segment elevation in I and aVL; this was
progressive during the balloon inﬂation). Ischemia is a well-known trigger of ventricular
arrhythmias in the setting of a forming myocardial scar which constitutes an arrhythmic substrate.
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contact with the endothelium has been recently visual-
ized (demonstrated qualitatively),
38 but no current
imaging technique can quantify this effect (i.e., deter-
mine the proportion of cells rolling in contact with
endothelium after the PC vs OTW delivery to the epi-
cardial artery). Thus, a later step in the ‘‘fate’’ of the
cells was quantiﬁed, i.e., the magnitude of early
engraftment inferred from percent activity uptake in the
myocardium (Figure 3). Secondly, the absence of ﬂow-
mediated endothelial rolling during balloon occlusion
(IRA ﬂow ceased) and the enhanced rapid cell washout
on balloon deﬂation could both be compensated by a
temporary ischemia-induced stimulation of cell-adhe-
sion mechanisms in the injury (border-) zone that may
occur with repeated IRA balloon inﬂations. It has been
shown, for instance, that the endothelial expression of
P-selectin on cardiac microvessels can be rapidly
up-regulated (via transportto the endothelial cell surface)
bybriefepisodesofischemia.
39,40Recentworkinthepig,
however, suggested a possible &30% reduction in
delivery efﬁciency for cell injection with an inﬂated vs.
non-inﬂated OTW balloon catheter (
111Indium cell
labeling; myocardial retention at one hour of 6.1% ±
2.5% vs 4.1% ± 1%),
41 whereas in this study PC-injec-
tions were not less effective than trans-OTW cells’
administration (Figure 3). Evidence shows that ﬂow-
mediated endothelial rolling is mandatory for subsequent
cell adhesion and extravasation in the zone of activated
endothelium.
5 Even if the side-holed PC method was
indeed successful in directing the cells towards the
endothelium, it might have no signiﬁcant impact on
the microcirculatory ﬂow (and thus cell uptake) because
the ‘‘distance’’ of rolling necessary for optimal down-
stream adhesion is undetermined.
5,38 A third (and not
unlikely) possibility is that the pool of native (non-engi-
neered) CD34
? cells used in clinical studies to-date may
contain only a fraction of cells that are ‘‘naturally’’
capable of colonizing the myocardial infarct injury zone
(i.e., possess a desirable pattern of receptors and appro-
priate functional capacity). This concept is exempliﬁed,
for instance, by the presence of the CXCR4 receptor in
less than 50% of CD34
? cells.
3 Although CXCR4 is
mandatory, it is not sufﬁcient for homing to the injury
zone.
42 This indicates that other (yet unidentiﬁed)
receptors are needed for CD34
? homing to the injured
myocardium, and only a fraction of CD34
? cells may
spontaneously express the ‘‘full’’ (desired) pattern.
Figure 2. Whole-body gamma-emission scans at 60 min after
transcoronary delivery of
99mTc-extametazime-labeled autolo-
gous CD34
? cells. Examples are from a patient with a large
anterior MI (4th quartile, A, left, note two peaks of myocardial
activity) and a relatively small anterior MI (1st quartile, B,
right, note diffuse activity that may correspond to the anterior
wall). LV is delineated in red. Myocardial activity was 6.52%
(A) and 2.21% (B) of whole-body gamma emission. Detailed
tomographic (SPECT) images from these two patients are
shown in Figure 3I( left panel) and II (right panel),
respectively.
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Figure 3. Box-plot presentation of % early myocardial reten-
tion of radioactivity 60 min after transcoroary delivery of
99mTc-extametazime-labeled autologous CD34
? cells with
coronary-occlusive (OTW, n = 13) versus non-occlusive per-
fusion (PC, n = 21) technique at 6-14 days after anterior MI
(random assignment on a 1:2 basis). The median value was
4.32% and 5.03% respectively (P = .84 for difference between
the groups). Myocardial activity uptake was expressed as %
total body activity and it was taken as an index of early
myocardial engraftment.
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It is not unexpected that selective transcoronary
approach is ineffective for cell delivery to the non-per-
fused myocardium because lack of tissue perfusion in
the infarcted area would prohibit direct uptake of tran-
scoronary-delivered cells in the infarct central zone
(Figure 4I). However, progenitor cells (including bone
marrow-derived tissue-committed stem cells)
5,42,43 are
known to migrate in the gradient of hypoxia-induced
chemokines such as SDF-1.
42,43 Recently, the gradient
of SDF-1 has been shown to increase 4-fold from the
border to the center of the infarct area,
44 indicating that
endogenous mechanisms can stimulate cell migration
from the infarct border-zone towards the center of the
forming scar. Potential determination of the magnitude
of this effect, however, was beyond the scope of this
study which was focused on short-term cell tracking
(
99mTc half-life is 6.03 h, fraction remaining is 50.2% at
6 h and 6.3% at 24 h). Peri-infarct (rather then infarct
central-zone) engraftment might contribute to the
apparent ineffectiveness of transcoronary-delivered cells
in patients with very large myocardial infarctions,
8
indicating that other delivery strategies
22,36 need to be
considered if cell therapy was aimed at large zones of
‘‘irreversible’’ injury. Due to its relatively low spatial
resolution (&8 mm) SPECT does not allow to evaluate
the transmural extent of the infarct.
45 Therefore, the
apparent diffuse pattern of early cells’ engraftment
(Figure 4II) that was detected in a small proportion of
patients (12%) may simply reﬂect a modest myocardial
injury, consistent with the relatively small necrotic
enzyme release in this patient group. Maintained
myocardial perfusion in the infarct injury zone (prior to
cell transfer) in subjects with relatively small MIs
(Figure 4II) could explain the ‘‘negative’’ outcome of
cell therapy in clinical studies including patients with
small MIs (c.f., e.g., the group with LVEF [49% in
REPAIR-AMI
7) who are a priori (i.e., without cellular
therapy) likely to experience only a mild residual
damage.
Strategies to Augment Homing
This study shows that, in humans, altering the
transcoronary delivery technique is unlikely to increase
the ‘‘poor’’ myocardial retention of native (non-engi-
neered) CD34
? cells delivered 6-14 days after pPCI
(Figure 3). Could the delivery efﬁciency be increased by
changing the timing of cell transplantation? This is
unlikely for the reasons as follows. First, the timing of
cell injections in our study was consistent with the peak
of spontaneous release of CD34
? cells from the bone
marrow after MI,
46,47 while data in animal models
indicate that the mechanisms attracting the cells to the
ischemic myocardium do not peak immediately after
AMI.
44 Second, clinical studies with cells delivery
within the ﬁrst 24 h of AMI have clearly demonstrated
no effect of cells injections
1,2 whereas functional data
from REPAIR-AMI (no treatment effect for cell transfer
at B4 days, the largest effect at 6-14 days)
7 are consis-
tent with the idea that cell administration should match
the peak of their spontaneous release from the bone
marrow. Indeed, recent study
11 on the relationship
between the time of progenitor cells administration and
their recruitment to the infracted human myocardium
(peak engraftment at 5-14 days; followed by a reduction
in engraftment proportional to the time after AMI)
indicate that timing of cell delivery in our study matched
the optimal potential for myocardial engraftment.
Individual patient data in this study (number of
infused CD34
? cells 9 proportion engraftment) show a
rough estimate of &40 000 to &400 000 CD34
? cells
taken up in the peri-infarct area, while it is known that
only 1:100 to 1:1000 CD34
? cells is a non-hematopoetic
progenitor. Even if mechanisms other than trans-differ-
entiation (for instance, paracrine effects) were to
drive myocardial regeneration,
48,49 this level of early
engraftment appears low relative to an average loss of
&1 billon myocytes and &2-3 billion other (such as
endothelial) cells with the typical MI in man.
48 Only a
fraction of early engrafted cells can survive and exhibit
long-term engraftment, and evidence accumulates that
the number of administered cells is likely to limit the
magnitude of the pro-regenerative effect in animals and
in man.
1,2,5,49,50
Direct needle injections (transepicardial or trans-
endocardial)
22,36,51,52 may lead to heightened, at least
initially, local cells retention but these are neither
physiological (for instance, the highly hypoxic milieu in
the center of the forming scar may reduce cell viabil-
ity
51) nor widely applicable in the clinical setting. Other
strategies to improve cell homing to the injured myo-
cardial tissue include pre-treatment of the cells (to
activate their incorporation in the damaged tissue) or
pre-treatment of the target tissue (to augment chemoat-
tractant factors).
5,49 Experimental work has identiﬁed
several mechanisms of progenitor cell homing to the
infarct injury zone, involving molecules such as HGF,
VEGF, ICAM-1, HMGB-1, and the SDF-1-CXCR4
axis.
5,42,43,53 Ex vivo activation of adhesion molecules
on the cell surface or over-expression of chemokine
receptors (such as CXCR4), the use of bispheric
antibodies recognizing myosin light chain, or intramy-
ocardial SDF-1 delivery have all been found promising
in animal models.
5,6,49 However, in mammals, healing
after acute ischemic events is naturally biased towards
scar formation and not regeneration of functional
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49; a constraint that remains to be overcome by
cell-based therapeutic strategies.
Study Limitations
In contrast to some other studies,
1-3,7,8,36 this study
was neither aimed nor powered to evaluate the potential
effect of cell transfer on functional recovery of infracted
myocardium. Much larger studies (e.g., REGENT with
200 patients randomized)
3 have been unable to resolve
this issue conclusively, since differentiation between
treatment-induced and spontaneous improvement is
extremelydifﬁcultwithstudyend-pointssuchasLVEF.
54
We deliberately focused on an ‘‘earlier’’ investigative
step, i.e., on a systematic evaluation of CD34
? cells’
myocardial uptake as a prerequisite for any potential
functional effect(s). Although this study population of
34 subjects may appear modest, recruitment of addi-
tional patients would be unlikely to impact the ﬁndings
since there was clearly no signal of any potential dif-
ference between engraftment efﬁciency with the two
techniques tested in this study. This study is not only
larger than a number of prior randomized studies
focused on stem cell therapy approaches
22 but it is also
the largest study to-date with labeled progenitor cells in
man (prior ones included a maximum of 5 to 8 subjects
with recent MI).
11,28,37
Direct labeling with radionuclides provides high-
sensitivity cell imaging and is the method of choice for
clinical studies that address homing and biodistribution
after cell injection.
19,20,32 One concern with radioactive
labeling is the potential radiation damage to the cell (the
likelihood of which increases with the label half-time)
20
and the other is an efﬂux of the label out of the cells,
leading to label loss from viable cells and to ‘‘false’’
indication of cell homing by the extracellular tracer.
20
While these concerns are unlikely to apply in any major
part to our study (
99mTc-extametazime spontaneous
wash-out from the labeled cells is\10% at 60 min), our
use of a radiotracer with a short half-life (T1/2 of 6.03 h
for
99mTc) reduces the time frame during which cells can
be imaged.
19,32 For this reason, the early retention of
radioactivity that we observed might partly reﬂect the
cells uptake in the ischemia-activated microcirculation
rather than an effective migration to the injured tissue.
Nevertheless, recent double-labeling experiments in the
murine heart indicated that c-counter quantiﬁcation of
99mTc-labeled progenitor cells homing to ischemic
muscle highly correlates with counting of immuno-
ﬂuorescent-stained engrafted cells,
53 providing an
additional validation of our technique. Although, due to
its longer half-life,
111In-oxime (T1/2 of 2.8 days) could
potentially allow in vivo cell imaging at later time-
points, this compound was consistently shown to
importantly reduce viability, migration and proliferation
of CD34
? progenitor cells.
25,26 Moreover, active elim-
ination of
111In-oxime from the cells ([70% eliminated
at 72 hours)
55 would introduce signiﬁcant errors to the
detection of cells at later time-points.
20 In contrast to
111In-oxime,
26,27 99mTc-labeling was found not to affect
cells’ functional capacity.
27,28
Presently, we have not performed cell migration
43
or clonogenicity
4 assays because the study was not
aimed at the functional effect of cell therapy and, to
maximize cell tracking, we decided that in each patient
all the isolated CD34
? cells would be used for tran-
scoronary transfer. Previously, however, we showed that
the trans-catheter passage had a negligible effect on cell
viability and clonogenicity.
4
For detailed evaluation of the cells myocardial
uptake zone(s), we used SPECT (and not magnetic
resonance imaging, MRI) because of its much greater
sensitivity for cell tracking (&10
3 cells with SPECT vs
&10
5 with MRI).
5,20,32,34 Moreover, MRI cell imaging
with the use of iron oxide tracers is prone to false
ﬁndings as a result of ferritin iron staining in the forming
MI scar
32 and of a rapid loss of signal speciﬁcity due to
phagocytosis of iron particles released from the cells.
19
The lower spatial resolution of SPECT visualization
compared to MRI
19,32 is the cost for high-sensitivity cell
tracking,
20,32 and it has not hampered our qualitative
evaluation of the early myocardial homing pattern
(Figure 4). Although it would be of interest to quantify
in detail the infarct border zone activity, central zone
activity, and the remote myocardial activity with our cell
injection techniques, this was not feasible since (1)
quantiﬁcation of the labeled cells myocardial uptake was
performed on whole body (planar) images, whereas the
qualitative evaluation of the pattern of early engraftment
(with image fusion) was performed on tomographic
images, and (2) with the resolution of SPECT or PET
(&6-8 mm)
45 it is impossible to reliably sub-divide (and
Figure 4. SPECT images of myocardial perfusion (day 7 after
MI; standard projections in A1-A3) and early myocardial
uptake of radioactivity (
99mTc-extametazime-labeled autolo-
gous CD34
? cells, day 9 after MI, B1-B3 are same projections
as A1-A3) in the OTW (left panel) and PC (right panel) group.
Integrated images combining the activity of labeled cells and
myocardial perfusion are shown in (C). Black arrows (top)
indicate the peri-infarct zone. Note the lack of perfusion in
septum, anterior wall and apex. Pink arrows (bottom) indicate
the maintained (albeit impaired) perfusion in the septum,
anterior wall and apex. Examples of the peri-infarct uptake of
99mTc-labeled cells activity (typical early engraftment pattern,
seen in 88% study patients) are in Figure 4I. Figure 4II shows
representative examples of a diffuse infarct activity uptake that
was seen in only 12% subjects who experienced a relatively
small ischemic injury (infarct size in the 1st quartile and the
LVEF in the 4th quartile by both echo and G-SPECT).
b
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the respective zones.
19,20,32,45 Indeed, even the use of
improved collimators for in vivo imaging or application
of histological techniques allow only qualitative rather
than quantitative analysis of labeled cells distribution
zone(s).
37,56
SPECT is unable to discriminate between infarcted
(dead) versus stunned tissue. Although (to minimize the
effect of stunning), we performed SPECT close (B36-
48 h) to cell delivery on the MI day 6-14, the early
uptake of radioactivity on the border of perfusion defect
in our study (Figure 4) may still reﬂect, in part, cells’
retention on the border of stunned (rather than infarcted)
tissue. This, however, has no major bearing on the
interpretation of our SPECT images that demonstrated
lack of cell radioactivity early uptake in the non-per-
fused infarct zone. Intensive development of hybrid
imaging techniques (e.g., reporter gene PET combined
with MRI using novel paramagnetic tracers
19)i s
expected to allow longer-term in vivo monitoring of cell
engraftment and survival.
19
While evaluation of distinct transcoronary delivery
strategies is clearly beyond the scope of small animal
models of MI,
57 it is unlikely that performing our study
in a large animal could lead to more insights with regard
to the efﬁciency of the distinct transcoronary cell
delivery techniques that we tested. We did initially
consider a preliminary study in the pig model of MI but
we took the decision against it for the following reasons:
(1) the PC technique is not novel to interventional car-
diology
15,16 and a pilot study in man already showed
that this technique is safe and feasible for transcoronary
cell delivery,
4 (2) for the two delivery methods tested,
no current imaging technique could quantify the pro-
portion of cells rolling in contact with endothelium or
proportion actually extravasating in the injury zone
(thus, with this respect, no animal model would be more
informative than the human data), (3) preclinical studies
are unlikely to predict the effectiveness of cell delivery
techniques in patients.
18 Moreover, the coronary-occlu-
sive (OTW) technique has already been used universally
in the clinical setting (over 1,500 patients in clinical
studies)
1-3 without any evidence for being required or
effective in stimulating engraftment.
6 This necessitated
testing the effectiveness of distinct transcoronary
delivery techniques directly in man,
6,11-13,18 as a pre-
requisite to looking for any potential therapeutic effect.
5
The use of histological techniques or other techniques
limited to animal models (such as reported gene assays)
to evaluate longer-term engraftment
19,20,32 would have
had a further role in the context of our study hypothesis
if the ‘‘basic’’
99mTc-labeled cell data SPECT had
showed any signal of a difference between the two
delivery methods that we tested.
The use of a whole-body single-planar scan with a
manual LV delineation could be associated with over-
estimation of myocardial engraftment due to inclusion
of tracer uptake by, for example, part of the lung. An
animal study could offer a direct quantiﬁcation of the
labeled cells activity in explanted organs rather than the
indirect evaluation from a whole-body (planar) scan.
Such study, however, had already been performed, and
heart-harvesting studies of radiolabeled cells homing in
the pig
33 have been consistent with whole-body cells’
imaging in the pig
41 and in man.
28,37 In addition, a
recent study on homing of
111In-labeled mesenchymal
stem cells in the pig
58 reported an excellent correlation
(r = 0.929) between ex vivo c-activity of the isolated
heart and other organs (lungs, kidneys, spleen, urinary
bladder) and the organ activity detected on a whole-
body scan.
Conclusions
This study, performed in patients with recent MI,
ﬁlls a long-standing gap in the essential need to evaluate
whether different transcoronary delivery strategies could
be useful for improving the poor myocardial engraft-
ment of (non-engineered) progenitor cells in
humans.
6,11-13 We found that the effectiveness of the
perfusion technique (side-holed perfusion catheter, cells
injections under maintained coronary ﬂow) is not dif-
ferent from that seen with the OTW-balloon method.
This indicates that the repeated coronary occlusions
(thus far adopted universally
1-3) are not required for
transcoronary administration of cellular therapies. In
addition to providing a guidewire security of the infarct-
related artery during cells administration, cell adminis-
tration under maintained coronary ﬂow does not provoke
transient ischemic episodes which are seen with the
stop-ﬂow (OTW) delivery and can affect the safety of
OTW cell delivery by triggering malignant arrhythmias.
For these reasons the perfusion technique provides a
viable alternative to the conventional coronary-occlu-
sive delivery of cellular therapies. Moreover, our
demonstration that retention of progenitor cells occurs
preferentially in the (viable) peri-infarct zone is con-
sistent with the idea that the infarct core zone may be
largely inaccessible to transcoronary-administered cells.
These ﬁndings may have implications for the
interpretation of current—and design of further—clini-
cal studies involving transcoronary delivery of cellular
therapies.
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